| 中芯国际 | 6.421Z | 5.18 亿 | 11.60亿 | | --- | --- | --- | --- | | HK 00981 | | | +1.24 亿 | | 快手-W | 4.62亿 | 4.71亿 | 9.33亿 | | HK 01024 | | | -850.31万 | | 石药集团 | 5.88亿 | 3.24亿 | 9.11亿 | | HK 01093 | | | +2.64 乙 | | 信达生物 | 6.77 亿 | 1.62亿 | 8.39亿 | | HK 01801 | | | +5.141Z | | 泡泡玛特 | 3.63亿 | 4.43亿 | 8.06亿 | | HK 09992 | | | -7973.47万 | 港股通(深)活跃成交股 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 小米集团-W HK 01810 | 31.76亿 | 21.87 亿 | 53.64亿 | | | | | +9.89 亿 | | 国泰君安 ... | 21.58亿 | 19.90亿 | 41 ...

| 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 小米集团-W(01810) | 53.64 亿元 | +9.89 亿元 | | 国泰君安国际(01788) | 41.48 亿元 | +1.69 亿元 | | 腾讯控股(00700) | 30.04 亿元 | +10.60 亿元 | | 阿里巴巴-W(09988) | 22.43 亿元 | +2.02 亿元 | | 中芯国际(00981) | 21.86 亿元 | +2.43 亿元 | | 美团-W(03690) | 20.67 亿元 | +2.21 亿元 | | 南方恒生科技(03033) | 16.71 亿元 | -6787.71 万元 | | 锦欣生殖(01951) | 15.63 亿元 | +1.95 亿元 | | 泡泡玛特(09992) | 15.31 亿元 | -2.72 亿元 | | 石药集团(01093) | 14.85 亿元 | +3.88 亿元 | 智通财经APP获悉，2025年7月29日当天，小米集团-W(01810)、国泰君安国际(01788)、腾讯控股 (00700)位居沪港通（南向）成交额前3 ...

在生物医药领域，"授权合作"是常见的模式，并从去年以来加速。 今年创新药行情由跨国药企高额交易驱动。 国际投行Jefferies认为，中国创新药研发性价比高、临床研发成本高，双方BD（商务开发）合作是强强联合，中国药企可借此提升全球商业化能力，但目前 仍处于起步阶段。 继人工智能、新消费等行业后，今年以来中国医药行业迎来了三年低迷后的逆袭。 创新药行情是由跨国药企高额交易所驱动的，美国大药企更是疯狂"扫货"中国管线，超过10亿美元的海外授权（Licensing-out）订单常态化。当前，创新药 行情热度依旧不减，众多生物医药企业排队等待港股IPO。 所谓"授权合作"，即中国药企将候选药物的部分权利（如全球开发、生产、商业化权利）授权给美国药企。中国药企通常仍然保留药物的专利权归属，并无 需建设自主全球商业化能力。美国药企拥有在协议范围内的独占许可权，有权在相关市场开展后续开发与销售，而中国企业则可获得里程碑付款（临床、注 册、销售等），并按药物在美国或全球的销售额获得一定比例（如5%~15%）。 根据港交所披露的数据，截至7月中旬，约有288家企业排队等待IPO，其中不乏生物医药企业试图通过18A规则上市。在 ...

Group 1 - Southbound funds net bought Hong Kong stocks worth 12.72 billion HKD today, with notable purchases in Xiaomi Group-W (1.659 billion), Tencent Holdings (0.832 billion), and Alibaba-W (0.753 billion) [1] - Southbound funds have net bought Tencent for four consecutive days, totaling 2.08902 billion HKD, and Xiaomi for three consecutive days, totaling 2.44603 billion HKD [1] - Other significant net purchases include Sino Biopharmaceutical (0.651 billion), InnoCare Pharma (0.514 billion), and SMIC (0.366 billion) [1] Group 2 - In the Shanghai Stock Connect, Xiaomi Group-W saw a decrease of 2.6% with a net buy of 0.989 billion, while Tencent Holdings increased by 0.1% with a net buy of 1.060 billion [3] - Alibaba-W had a slight increase of 0.1% with a net buy of 0.202 billion, and SMIC rose by 0.5% with a net buy of 0.243 billion [3] - Meituan-W experienced a decline of 0.6% with a net sell of 0.221 billion, while Pop Mart saw a significant increase of 5.9% with a net sell of 0.272 billion [3]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant growth in various time frames [1] - As of June 30, 2025, the fund's latest net value is 0.8101 yuan, reflecting a growth of 4.14% [1] - The fund has achieved a one-month return of 21.65%, a six-month return of 64.72%, and a year-to-date return of 63.33%, with respective rankings of 296 out of 4764, 63 out of 4579, and 72 out of 4542 in its category [1] Group 2 - The top ten stock holdings of the fund account for a total of 61.79%, with significant positions in companies such as Sanofi (10.07%), Innovent Biologics (8.94%), and Kelun-Biotech (8.71%) [1] - The fund was established on August 21, 2020, and as of June 30, 2025, it has a total scale of 1.922 billion yuan [1] - The fund manager is Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2]

智通财经7月28日电，香港交易所信息显示，贝莱德在信达生物的持股比例于07月22日从4.63%升至 5.19%。 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]

Summary of Conference Call Records Industry Overview - The Chinese innovative pharmaceutical industry is experiencing accelerated development, driven by internationalization, policy support, and technological breakthroughs [3][4] - The recognition of Chinese innovative drugs in international markets is increasing, with a notable rise in BD (business development) transactions and large upfront payments [1][3] Key Companies Innovent Biologics (信达生物) - Sales revenue from tumor products has rapidly increased, surpassing 8 billion RMB in 2024 and expected to reach 11 billion RMB in 2025 [1] - IBI363 shows significant efficacy in lung cancer and colorectal cancer, with a 12-month overall survival (OS) rate of 70.9% in lung cancer patients [7][8] - The company has a strong competitive advantage in the tumor field, with multiple potential products and a robust pipeline [9] - Non-tumor products like Masudutai and others are also entering the sales phase, with peak sales expected to exceed 8 billion RMB [10] Kangfang Biopharma (康方生物) - Revenue growth is projected to exceed 70% in 2025 and around 40% in 2026, driven by continuous product approvals and market expansion [1][13] - AK112, a core product targeting PD-1 and VEGF, shows rapid clinical advancement and high safety, particularly in squamous cell carcinoma [14][15] - The company is actively pursuing early treatment research for PD-1 resistant patients, differentiating itself from competitors [2][17] Technological Breakthroughs - Innovations in ADC (Antibody-Drug Conjugates), IO (Immuno-Oncology) bispecific antibodies, GLP-1, and T-cell engagers are leading industry advancements [1][3] - Kangfang's dual antibody technology platform has significantly improved R&D success rates, with rapid approval timelines for key products [13] Investment Insights - Recommended investment targets include companies like Heng Rui Medicine, BeiGene, and others in both A-share and H-share markets [5] - Key investment considerations include overseas sales potential and anticipated business development activities [4] Future Catalysts - For Innovent, upcoming catalysts include the initiation of clinical trials for various products and expected data readouts in 2026 [11] - Kangfang is expected to continue rapid progress in overseas clinical research and expand its market presence [18][24] Market Valuation - Kangfang's current reasonable market value is estimated at 200.098 billion RMB, with a target price of 222.93 RMB based on DCF model calculations [25]

Core Viewpoint - The rapid growth of overseas licensing transactions by Chinese innovative pharmaceutical companies marks the beginning of a commercial explosion in the industry, with expectations for significant sales and revenue increases in the coming years [1][5][6]. Group 1: Market Growth and Trends - The total amount of overseas licensing transactions by Chinese pharmaceutical companies is projected to reach $51.9 billion in 2024, a 36% increase from the previous year, and exceed $60.8 billion in the first half of 2025 [6]. - The innovative drug sector in China is expected to experience a convergence of three pivotal turning points: explosive sales of previously approved drugs, substantial increases in overseas revenue, and an overall upgrade in the industry's profit model [1][8]. - The cumulative increase in the A-share Innovative Drug 50 ETF is 21%, while the Hong Kong Hang Seng Innovative Drug ETF has surged by 56% [4]. Group 2: Industry Evolution - Since the 2015 reform of drug and medical device review and approval systems, the Chinese innovative drug industry has transitioned from a focus on capability building to a phase of full-scale market realization [1][24]. - The number of approved innovative drugs in China has surged to over 40 in 2024, nearly a tenfold increase since 2015, with R&D investment rising from approximately 50 billion yuan to over 121 billion yuan [24][26]. Group 3: Licensing and Collaboration - Chinese innovative pharmaceutical companies are increasingly binding themselves to leading multinational firms through licensing agreements, which are seen as a means to share risks and enhance R&D capabilities [12][13]. - The trend of overseas licensing is expected to continue, driven by the strong demand from multinational companies for external innovative assets amid patent cliffs [8][12]. Group 4: Future Catalysts and Innovations - The period from 2023 to 2026 is anticipated to be critical for the industry, with a significant number of drugs expected to enter the market, leading to accelerated revenue growth [8][9]. - Emerging technologies such as AI and brain-computer interfaces (BCI) are reshaping drug innovation and treatment methodologies, with AI significantly reducing the time and cost of drug development [17][20]. Group 5: Challenges and Strategic Considerations - Concerns exist regarding the potential for Chinese companies to "sell seedlings," meaning they may be too eager to license early-stage assets for short-term gains, potentially missing out on larger future opportunities [11][12]. - The industry faces challenges related to the high-risk nature of innovative drug development, with many biotech firms having to downsize or exit the market during recent capital downturns [25][26].

Group 1 - The core viewpoint of the articles highlights that the proportion of actively managed equity funds holding Hong Kong stocks has reached a historical high, driven by a significant increase in global interest in Chinese assets [1][3]. - As of the end of Q2, the total market value of Hong Kong stocks held by public funds reached 734.3 billion yuan, a 12.8% increase from the previous quarter, with the proportion of public fund holdings in Hong Kong stocks rising from 36.9% to 39.8% [2]. - The actively managed equity funds specifically increased their holdings in the healthcare and financial sectors while reducing exposure in information technology and discretionary consumer sectors [2]. Group 2 - The Hang Seng Index has seen a year-to-date increase of nearly 27%, making it the best-performing major index globally, with fund managers expressing optimism about the market's future [4]. - Fund managers are particularly optimistic about structural opportunities in various sectors, including new consumption, innovative pharmaceuticals, and traditional industries like "AI+", overseas expansion, and smart manufacturing [4]. - The increasing allocation of public funds to Hong Kong stocks reflects a growing attractiveness of the market, with over 50% of public funds now having the ability to invest in Hong Kong stocks as of Q2 2025 [3].